May 2011

  • UI Program Builds Research, Education Ties Across Iowa

    The FUTURE in Biomedicine program aims to strengthen science education and research across the state by developing partnerships between faculty from the UI and professors and students from Iowa undergraduate colleges.

  • Addressing Feeding Disorders

    The Pediatric Feeding Disorders Service at UI Children’s Hospital is the only one of its kind in Iowa and one of just a handful in the Midwest.

  • UI Researchers Recognized by JDRF

    Researchers from the UI Carver College of Medicine's Department of Pediatrics were honored in May for their work with the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group.

  • Top Children's Rankings

    UI Children's Hospital ranks among the nation's top children's hospitals, according to U.S.News & World Report's 2011-2012 edition of "Best Children's Hospitals."
  • Reporting World-Class Activities

    Explore breakthrough discoveries, educational advances and innovative patient care in UI Health Care's Annual Report.

  • NIH Awards $4 Million Training Grant for Cardiovascular Research Center

    The National Heart, Lung and Blood Institute, part of the National Institutes of Health, has granted the Carver College of Medicine a five-year, $4 million Institutional National Research Service Award renewal. 

  • UI Launches $500 Million Fundraising Campaign for UI Health Care

    The University of Iowa publicly launched "Iowa First: Our Campaign for Breakthrough Medicine," a $500 million fundraising campaign for UI Health Care, and announced that donors have given more than $314 million for the campaign so far.


  • A Gift for Children's Medicine

    A $10 million gift from Jerre and Mary Joy Stead will advance children’s medicine at the University of Iowa.


  • UI-led Research Team Identifies Receptor for Ebola Virus

    A team of researchers has identified a cellular protein that acts as a receptor for Ebola virus and Marburg virus. Furthermore, the team showed that an antibody, which binds to the receptor protein, is able to block infection by both viruses. 

  • Study Finds Avastin, Lucentis Equally Effective for Age-related Macular Degeneration

    Researchers are reporting results from the first year of a two-year clinical trial that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration (AMD), is as effective as the Food and Drug Administration-approved drug Lucentis for the treatment of AMD.